ACM
BMY.RT

Avalon Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Avalon Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,870
Closed -$36K – 40
2019
Q4 		$36K Buy
+11,870
New +$30.9K 0.04% 32

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Avalon Capital Management's BMY.RT Position: Q1 2020 in Review

Avalon Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2020, closing a stake of 11,870 shares — an estimated $36K sold.

Avalon Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 1 quarter. The position peaked at $36K in Q4 2019. 581 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2020.

  • Avalon Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
  • Avalon Capital Management sold 11,870 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2020, an estimated $36K.
  • Avalon Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 1 quarter.
  • Avalon Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $36K in Q4 2019.
  • 581 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2020.

Based on Avalon Capital Management's 13F filing for Q1 2020, filed 20 Apr 2020.